Bangladesh
· Delayed Price · Currency is BDT Navana Pharmaceuticals Statistics
Total Valuation
Navana Pharmaceuticals has a market cap or net worth of BDT 7.16 billion. The enterprise value is 11.63 billion.
| Market Cap | 7.16B |
| Enterprise Value | 11.63B |
Important Dates
The next estimated earnings date is Tuesday, October 22, 2024.
| Earnings Date | Oct 22, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Navana Pharmaceuticals has 107.42 million shares outstanding. The number of shares has increased by 16.28% in one year.
| Shares Outstanding | 107.42M |
| Shares Change (YoY) | +16.28% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 35.49% |
| Owned by Institutions (%) | n/a |
| Float | 69.30M |
Valuation Ratios
The trailing PE ratio is 16.30.
| PE Ratio | 16.30 |
| Forward PE | n/a |
| PS Ratio | 1.10 |
| PB Ratio | 1.58 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.81, with an EV/FCF ratio of -13.87.
| EV / Earnings | 26.44 |
| EV / Sales | 1.79 |
| EV / EBITDA | 10.81 |
| EV / EBIT | 13.44 |
| EV / FCF | -13.87 |
Financial Position
The company has a current ratio of 0.95, with a Debt / Equity ratio of 108.52.
| Current Ratio | 0.95 |
| Quick Ratio | 0.23 |
| Debt / Equity | 108.52 |
| Debt / EBITDA | 4.56 |
| Debt / FCF | -5.85 |
| Interest Coverage | 2.95 |
Financial Efficiency
Return on equity (ROE) is 9.87% and return on invested capital (ROIC) is 6.12%.
| Return on Equity (ROE) | 9.87% |
| Return on Assets (ROA) | 5.62% |
| Return on Capital (ROIC) | 6.12% |
| Revenue Per Employee | 1.57M |
| Profits Per Employee | 106,205 |
| Employee Count | 4,143 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 1.48 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.37% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -33.37% |
| 50-Day Moving Average | 79.97 |
| 200-Day Moving Average | 87.83 |
| Relative Strength Index (RSI) | 40.67 |
| Average Volume (20 Days) | 341,505 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Navana Pharmaceuticals had revenue of BDT 6.50 billion and earned 440.01 million in profits. Earnings per share was 4.09.
| Revenue | 6.50B |
| Gross Profit | 2.99B |
| Operating Income | 865.75M |
| Pretax Income | 566.74M |
| Net Income | 440.01M |
| EBITDA | 1.02B |
| EBIT | 865.75M |
| Earnings Per Share (EPS) | 4.09 |
Balance Sheet
The company has 328.92 million in cash and 4.91 billion in debt, giving a net cash position of -4.47 billion or -41.59 per share.
| Cash & Cash Equivalents | 328.92M |
| Total Debt | 4.91B |
| Net Cash | -4.47B |
| Net Cash Per Share | -41.59 |
| Equity (Book Value) | 4.52B |
| Book Value Per Share | 42.11 |
| Working Capital | -254.50M |
Cash Flow
In the last 12 months, operating cash flow was 88.89 million and capital expenditures -927.34 million, giving a free cash flow of -838.44 million.
| Operating Cash Flow | 88.89M |
| Capital Expenditures | -927.34M |
| Free Cash Flow | -838.44M |
| FCF Per Share | -7.81 |
Margins
Gross margin is 46.02%, with operating and profit margins of 13.31% and 6.77%.
| Gross Margin | 46.02% |
| Operating Margin | 13.31% |
| Pretax Margin | 8.71% |
| Profit Margin | 6.77% |
| EBITDA Margin | 15.72% |
| EBIT Margin | 13.31% |
| FCF Margin | -12.89% |
Dividends & Yields
This stock pays an annual dividend of 1.30, which amounts to a dividend yield of 1.95%.
| Dividend Per Share | 1.30 |
| Dividend Yield | 1.95% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 30.22% |
| Buyback Yield | -16.28% |
| Shareholder Yield | -14.33% |
| Earnings Yield | 6.13% |
| FCF Yield | -11.70% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |